Reply to the letter to the editor 'Anti-EGFR therapy in oesophagogastric cancer: precise but not enough' by M. Salati and S. Cascinu.

Ruhstaller, T; Langer, R; Thuss-Patience, P; Eisterer, W; Stahl, M

Ruhstaller, T; Langer, R; Thuss-Patience, P; Eisterer, W; Stahl, M.

Afiliação

Ruhstaller T; Department of Oncology and Haematology, Cantonal Hospital of St. Gallen, St. Gallen.
Langer R; Institute of Pathology, University Hospital of Berne, Berne, Switzerland.
Thuss-Patience P; Department of Haematology, Oncology and Tumorimmunology, University Medicine, Berlin, Germany.
Eisterer W; Medical Department, Medical University, Innsbruck, Austria.
Stahl M; Medical Oncology, Kliniken Essen-Mitte, Essen, Germany.

Ann Oncol ; 29(9): 2018, 2018 09 01.

Article em En | MEDLINE | ID: mdl-29992287

Assuntos

Neoplasias Esofágicas; Terapia Neoadjuvante; Cetuximab; Quimiorradioterapia; Receptores ErbB; Humanos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Terapia Neoadjuvante Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google